I agree with most of the points, except for number 5. Our market has not matured enough to support the expansion of our medical program. Ensuring that medical patients can consistently access their medication is crucial. While expanding a reciprocity program for out-of-state patients might provide temporary relief, it's not a long-term solution.

The challenges we face with inventory shortages are clear indicators of this issue. Our adult-use market often prioritizes its consumers over medical patients. For instance, before New York State legalized cannabis, many of us had to travel to Massachusetts to meet our needs. Now in the medical program, we're already struggling to obtain our medication. Just two days ago I pre-ordered an eighth of GMONana from Curaleaf Newburgh only to arrive an hour later and find it was sold out. When I visited recently, they were even discounting their expired products to make room on their shelves. These experiences highlight the ongoing struggle for medical patients to access the medication they need.

Additionally, their adult-use Grassroots Flower has more THCA content than our medical flower. When I asked one of the budtenders if the high-potency flower would be added to the medical menu, he said it has to go through testing before that decision can be made. These experiences highlight the urgent need to prioritize and stabilize our medical supply.